Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

autologous ovarian cancer immunogene-modified T lymphocytes

A preparation of autologous immunogene modified T lymphocytes (IgT) that have been genetically engineered to be specifically reactive to ovarian cancer (OC) cells, with potential antineoplastic and immunostimulating activities. Upon administration of the autologous OC-IgT cells, the T cells recognize and induce specific toxicity in the OC cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous human OC-IgT cells
OC-IgT cells
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search